Cronos Group Inc. (CRON) stock
CRONNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 15/3010% below fair value
$3.19−0.08 (-2.45%)
Close on Nov 17, 2026Market cap $1.18BP/E 15.9Yield –
Cronos revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Cronos's revenue for the twelve months ending Jun 30, 2026 was $179.09M, up 37.5% year over year. For fiscal 2025 it was $146.59M, up 24.6% from the year before. The highest annual figure on record is $146.59M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $146.59M | +24.6% |
| FY2024 | Dec 31, 2024 | $117.62M | +34.8% |
| FY2023 | Dec 31, 2023 | $87.24M | +0.6% |
| FY2022 | Dec 31, 2022 | $86.75M | +34.4% |
| FY2021 | Dec 31, 2021 | $64.56M | +38.2% |
| FY2020 | Dec 31, 2020 | $46.72M | +96.7% |
| FY2019 | Dec 31, 2019 | $23.75M | +95.9% |
| FY2018 | Dec 31, 2018 | $12.12M | +285.2% |
| FY2017 | Dec 31, 2017 | $3.15M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $53.01M | +58.4% |
| Q1 FY2026 | Mar 31, 2026 | $45.21M | +40.1% |
| Q4 FY2025 | Dec 31, 2025 | $44.53M | +47.0% |
| Q3 FY2025 | Sep 30, 2025 | $36.34M | +6.1% |
| Q2 FY2025 | Jun 30, 2025 | $33.46M | +20.5% |
| Q1 FY2025 | Mar 31, 2025 | $32.26M | +27.6% |
| Q4 FY2024 | Dec 31, 2024 | $30.30M | +26.7% |
| Q3 FY2024 | Sep 30, 2024 | $34.26M | +38.1% |
| Q2 FY2024 | Jun 30, 2024 | $27.76M | +46.0% |
| Q1 FY2024 | Mar 31, 2024 | $25.29M | +29.7% |
| Q4 FY2023 | Dec 31, 2023 | $23.92M | +8.5% |
| Q3 FY2023 | Sep 30, 2023 | $24.81M | +21.6% |
| Q2 FY2023 | Jun 30, 2023 | $19.02M | -11.9% |
| Q1 FY2023 | Mar 31, 2023 | $19.50M | -22.1% |
| Q4 FY2022 | Dec 31, 2022 | $22.03M | +38.4% |
| Q3 FY2022 | Sep 30, 2022 | $20.41M | +0.0% |
| Q2 FY2022 | Jun 30, 2022 | $21.60M | +38.3% |
| Q1 FY2022 | Mar 31, 2022 | $25.03M | +98.5% |
| Q4 FY2021 | Dec 31, 2021 | $15.92M | -6.6% |
| Q3 FY2021 | Sep 30, 2021 | $20.41M | +79.7% |
| Q2 FY2021 | Jun 30, 2021 | $15.62M | +58.1% |
| Q1 FY2021 | Mar 31, 2021 | $12.61M | +49.6% |
| Q4 FY2020 | Dec 31, 2020 | $17.05M | +133.3% |
| Q3 FY2020 | Sep 30, 2020 | $11.36M | +96.3% |
| Q2 FY2020 | Jun 30, 2020 | $9.88M | +29.1% |
| Q1 FY2020 | Mar 31, 2020 | $8.43M | +180.7% |
| Q4 FY2019 | Dec 31, 2019 | $7.31M | +70.5% |
| Q3 FY2019 | Sep 30, 2019 | $5.79M | +101.1% |
| Q2 FY2019 | Jun 30, 2019 | $7.65M | +191.0% |
| Q1 FY2019 | Mar 31, 2019 | $3.00M | +29.0% |
| Q4 FY2018 | Dec 31, 2018 | $4.29M | – |
| Q3 FY2018 | Sep 30, 2018 | $2.88M | – |
| Q2 FY2018 | Jun 30, 2018 | $2.63M | – |
| Q1 FY2018 | Mar 31, 2018 | $2.33M | – |
See a number that looks wrong?